Two safe and effective RV vaccines (Rotarix, GlaxoSmithKline Biologicals, Belgium and RotaTeq, Merck Inc., USA) have been licensed in approximately 100 countries

worldwide since 2006 [4]. These vaccines have already been incorporated into the routine immunization programs in many countries of the Americas and Europe, as well as in Australia and South Africa [5]. With the 2009 World Health Organization (WHO) recommendation for the global use of RV vaccines [6], it is anticipated that these vaccines will soon be introduced more widely in immunization programs globally. RV expresses two surface proteins – NLG919 manufacturer VP7, which determines the G type specificity and VP4, which determines the P type specificity – that act as neutralizing antigens to elicit this website protective humoral immune responses. Since VP7 and VP4 are encoded by separate genome segments, both (sero)type specificity and type-specific immunity segregate in an independent manner [7]. By the early 2000s, global surveillance studies had identified at least 10 G and 11 P antigen types among

human rotavirus strains [8] and [9]. While these independently segregating G and P antigens could theoretically generate 110 unique strains through reassortment in vivo during mixed infections between strains with different types, 5 strains (G1P [8], G2P [4], G3P [8], G4P [8], and G9P [8]) have been found to be responsible for the majority of severe RV infections worldwide [8] and [9]. Additional strains with unusual antigen types or unusual combinations of common G and P types have been also identified, showing notable differences in some geographic areas. This remarkable Sodium butyrate diversity of human RV strains is associated with 3 major evolutionary mechanisms: accumulation of point mutations leading to antigenic drift; reassortment of cognate genome segments to promote antigenic shift; and zoonotic transmission of animal strains to introduce antigen types new into humans [10] and [11]. RV vaccination strategies have evolved with trials conducted with

various vaccine candidates, without solid knowledge of the mechanisms and mediators of protective immunity [12]. The relative importance of heterotypic and homotypic immunity to RV is still debated; however, evidence suggests that both may be important. Epidemiologic observations and animal experiments indicate that first RV infections elicit primarily homotypic antibodies, while subsequent infections evoke both homotypic and heterotypic immune responses [13], [14] and [15]. Both current licensed vaccines are administered in multiple doses (2 doses for Rotarix and 3 doses for RotaTeq), in part to mimic the immune response to natural RV infection and elicit both homotypic and heterotypic immunity [13], [16], [17] and [18].